Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Osteosarcoma 1Melanoma 1Breast Neoplasms 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × CR011-vcMMAE × Clear all
NCT00412828 2015-02-19

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Celldex Therapeutics

Phase 1/2 Completed
117 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡